Recent advances in RASopathies

Journal of Human Genetics

Volumn 61, Issue 1, 2016, Pages 33-39

  Aoki, Yoko ^a   Niihori, Tetsuya ^a   Inoue, Shin Ichi ^a   Matsubara, Yoichi ^b  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN;

A2ML1 GENE; ARTERIOVENOUS MALFORMATION; CARDIOVASCULAR MALFORMATION; COSTELLO SYNDROME; GENE; GENETIC DISORDER; GERMLINE MUTATION; GINGIVA FIBROMATOSIS; HUMAN; LEGIUS SYNDROME; LEOPARD SYNDROME; LZTR1 GENE; NEUROFIBROMATOSIS TYPE 1; NONHUMAN; NOONAN LIKE SYNDROME; NOONAN SYNDROME; RAS MITOGEN ACTIVATED PROTEIN KINASE SYNDROME; RASA2 GENE; REVIEW; RIT1 GENE; RRAS GENE; SOS2 GENE; GENETICS; SIGNAL TRANSDUCTION; SYNDROME;

CARDIOVASCULAR ABNORMALITIES; GERM-LINE MUTATION; HUMANS; MAP KINASE SIGNALING SYSTEM; NOONAN SYNDROME; RAS PROTEINS; SYNDROME;

EID: 84955462698     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2015.114     Document Type: Review

References (77)

1. Malumbres, M., & Barbacid, M. RAS oncogenes: the first 30 years. Nat. Rev. Cancer. 3, 459-465 (2003).
2. Aoki, Y., Niihori, T., Narumi, Y., Kure, S., & Matsubara, Y. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum. Mutat. 29, 992-1006 (2008).
3. Tidyman, W. E., & Rauen, K. A. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr. Opin. Genet. Dev. 19, 230-236 (2009).
4. Rauen, K. A. The RASopathies. Annu. Rev. Genomics Hum. Genet. 14, 355-369 (2013).
5. Friedman, J. M. Neurofibromatosis 1. GeneReviews® [Internet] (University of Washington, Seattle, WA, 2014).
6. Viskochil, D., Buchberg, A. M., Xu, G., Cawthon, R. M., Stevens, J., Wolff, R. K., et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62, 187-192 (1990).
7. Wallace, M. R., Marchuk, D. A., Andersen, L. B., Letcher, R., Odeh, H. M., Saulino, A. M., et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249, 181-186 (1990).
8. Brems, H., Chmara, M., Sahbatou, M., Denayer, E., Taniguchi, K., Kato, R., et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat. Genet. 39, 1120-1126 (2007).
9. Pandit, B., Sarkozy, A., Pennacchio, L. A., Carta, C., Oishi, K., Martinelli, S., et al. Gainof-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat. Genet. 39, 1007-1012 (2007).
10. Razzaque, M. A., Nishizawa, T., Komoike, Y., Yagi, H., Furutani, M., Amo, R., et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat. Genet. 39, 1013-1017 (2007).
11. Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 29, 465-468 (2001).
12. Tartaglia, M., Pennacchio, L. A., Zhao, C., Yadav, K. K., Fodale, V., Sarkozy, A., et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat. Genet. 39, 75-79 (2007).
13. Schubbert, S., Zenker, M., Rowe, S. L., Boll, S., Klein, C., Bollag, G., et al. Germline KRAS mutations cause Noonan syndrome. Nat. Genet. 38, 331-336 (2006).
14. Cirstea, I. C., Kutsche, K., Dvorsky, R., Gremer, L., Carta, C., Horn, D., et al. A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat. Genet. 42, 27-29 (2010).
15. Sarkozy, A., Carta, C., Moretti, S., Zampino, G., Digilio, M. C., Pantaleoni, F., et al. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum. Mutat. 30, 695-702 (2009).
16. Digilio, M. C., Conti, E., Sarkozy, A., Mingarelli, R., Dottorini, T., Marino, B., et al. Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am. J. Hum. Genet. 71, 389-394 (2002).
17. Aoki, Y., Niihori, T., Kawame, H., Kurosawa, K., Ohashi, H., Tanaka, Y., et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat. Genet. 37, 1038-1040 (2005).
18. Niihori, T., Aoki, Y., Narumi, Y., Neri, G., Cave, H., Verloes, A., et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat. Genet. 38, 294-296 (2006).
19. Rodriguez-Viciana, P., Tetsu, O., Tidyman, W. E., Estep, A. L., Conger, B. A., Cruz, M. S., et al. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311, 1287-1290 (2006).
20. Cordeddu, V., Di Schiavi, E., Pennacchio, L. A., Ma'ayan, A., Sarkozy, A., Fodale, V., et al. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat. Genet. 41, 1022-1026 (2009).
21. Martinelli, S., De Luca, A., Stellacci, E., Rossi, C., Checquolo, S., Lepri, F., et al. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am. J. Hum. Genet. 87, 250-257 (2010).
22. Niemeyer, C. M., Kang, M. W., Shin, D. H., Furlan, I., Erlacher, M., Bunin, N. J., et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat. Genet. 42, 794-800 (2010).
23. Perez, B., Mechinaud, F., Galambrun, C., Ben Romdhane, N., Isidor, B., Philip, N., et al. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia. J. Med. Genet. 47, 686-691 (2010).
24. Hart, T. C., Zhang, Y., Gorry, M. C., Hart, P. S., Cooper, M., Marazita, M. L., et al. A mutation in the SOS1 gene causes hereditary gingival fibromatosis type 1. Am. J. Hum. Genet. 70, 943-954 (2002).
25. Eerola, I., Boon, L. M., Mulliken, J. B., Burrows, P. E., Dompmartin, A., Watanabe, S., et al. Capillary malformation-Arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am. J. Hum. Genet. 73, 1240-1249 (2003).
26. Romano, A. A., Allanson, J. E., Dahlgren, J., Gelb, B. D., Hall, B., Pierpont, M. E., et al. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 126, 746-759 (2010).
27. Allanson, J. E., Hall, J. G., Hughes, H. E., Preus, M., & Witt, R. D. Noonan syndrome: the changing phenotype. Am. J. Med. Genet. 21, 507-514 (1985).
28. Van Der Burgt, I. Noonan syndrome. Orphanet J. Rare Dis. 2, 4 (2007).
29. Aoki, Y., Niihori, T., Banjo, T., Okamoto, N., Mizuno, S., Kurosawa, K., et al. Gain-offunction mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am. J. Hum. Genet. 93, 173-180 (2013).
30. Wes, P. D., Yu, M., & Montell, C. RIC, a calmodulin-binding Ras-like GTPase. EMBO J. 15, 5839-5848 (1996).
31. Lee, C. H., Della, N. G., Chew, C. E., & Zack, D. J. Rin, a neuron-specific and calmodulin-binding small G-protein, and Rit define a novel subfamily of ras proteins. J. Neurosci. 16, 6784-6794 (1996).
32. Rusyn, E. V., Reynolds, E. R., Shao, H., Grana, T. M., Chan, T. O., Andres, D. A., et al. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways. Oncogene. 19, 4685-4694 (2000).
33. Sakabe, K., Teramoto, H., Zohar, M., Behbahani, B., Miyazaki, H., Chikumi, H., et al. Potent transforming activity of the small GTP-binding protein Rit in NIH 3T3 cells: evidence for a role of a p38gamma-dependent signaling pathway. FEBS Lett. 511, 15-20 (2002).
34. Spencer, M. L. Induction of neurite extension and survival in pheochromocytoma cells by the Rit GTPase. J. Biol. Chem. 277, 20160-20168 (2002).
35. Chen, P. C., Yin, J., Yu, H. W., Yuan, T., Fernandez, M., Yung, C. K., et al. Nextgeneration sequencing identifies rare variants associated with Noonan syndrome. Proc. Natl. Acad. Sci. USA 111, 11473-11478 (2014).
36. Bertola, D. R., Yamamoto, G. L., Almeida, T. F., Buscarilli, M., Jorge, A. A., Malaquias, A. C., et al. Further evidence of the importance of RIT1 in Noonan syndrome. Am. J. Med. Genet. A 164A, 2952-2957 (2014).
37. Gos, M., Fahiminiya, S., Poznanski, J., Klapecki, J., Obersztyn, E., Piotrowicz, M., et al. Contribution of RIT1 mutations to the pathogenesis of Noonan syndrome: four new cases and further evidence of heterogeneity. Am. J. Med. Genet. A 164A, 2310-2316 (2014).
38. Berger, A. H., Imielinski, M., Duke, F., Wala, J., Kaplan, N., Shi, G. X., et al. Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene. 33, 4418-4423 (2014).
39. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550 (2014).
40. Gomez-Segui, I., Makishima, H., Jerez, A., Yoshida, K., Przychodzen, B., Miyano, S., et al. Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies. Leukemia 27, 1943-1946 (2013).
41. Flex, E., Jaiswal, M., Pantaleoni, F., Martinelli, S., Strullu, M., Fansa, E. K., et al. Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. Hum. Mol. Genet. 23, 4315-4327 (2014).
42. Reuther, G. W., & Der, C. J. The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr. Opin. Cell. Biol. 12, 157-165 (2000).
43. Vissers, L. E., Bonetti, M., Paardekooper Overman, J., Nillesen, W. M., Frints, S. G., De Ligt, J., et al. Heterozygous germline mutations in A2ML1 are associated with a disorder clinically related to Noonan syndrome. Eur. J. Hum. Genet. 23, 317-324 (2015).
44. Galliano, M. F., Toulza, E., Gallinaro, H., Jonca, N., Ishida-Yamamoto, A., Serre, G., et al. A novel protease inhibitor of the alpha2-macroglobulin family expressed in the human epidermis. J. Biol. Chem. 281, 5780-5789 (2006).
45. Numata, S., Teye, K., Tsuruta, D., Sogame, R., Ishii, N., Koga, H., et al. Anti-Alpha-2- macroglobulin-like-1 autoantibodies are detected frequently and may be pathogenic in paraneoplastic pemphigus. J. Invest. Dermatol. 133, 1785-1793 (2013).
46. Schepens, I., Jaunin, F., Begre, N., Laderach, U., Marcus, K., Hashimoto, T., et al. The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. PLoS ONE 5, e12250 (2010).
47. Galliano, M. F., Toulza, E., Jonca, N., Gonias, S. L., Serre, G., & Guerrin, M. Binding of alpha2ML1 to the low density lipoprotein receptor-related protein 1 (LRP1) reveals a new role for LRP1 in the human epidermis. PLoS ONE 3, e2729 (2008).
48. Takayama, Y., May, P., Anderson, R. G., & Herz, J. Low density lipoprotein receptorrelated protein 1 (LRP1) controls endocytosis and c-CBL-mediated ubiquitination of the platelet-derived growth factor receptor beta (PDGFR beta). J. Biol. Chem. 280, 18504-18510 (2005).
49. Yamamoto, G. L., Aguena, M., Gos, M., Hung, C., Pilch, J., Fahiminiya, S., et al. Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome. J. Med. Genet. 52, 413-421 (2015).
50. Frattini, V., Trifonov, V., Chan, J. M., Castano, A., Lia, M., Abate, F., et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat. Genet. 45, 1141-1149 (2013).
51. Piotrowski, A., Xie, J., Liu, Y. F., Poplawski, A. B., Gomes, A. R., Madanecki, P., et al. Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat. Genet. 46, 182-187 (2014).
52. Kurahashi, H., Akagi, K., Inazawa, J., Ohta, T., Niikawa, N., Kayatani, F., et al. Isolation and characterization of a novel gene deleted in DiGeorge syndrome. Hum. Mol. Genet. 4, 541-549 (1995).
53. Kobayashi, T., Aoki, Y., Niihori, T., Cavé, H., Verloes, A., Okamoto, N., et al. Molecular and clinical analysis of RAF1in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation. Hum. Mutat. 31, 284-294 (2010).
54. Hanna, N., Montagner, A., Lee, W. H., Miteva, M., Vidal, M., Vidaud, M., et al. Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1. FEBS Lett. 580, 2477-2482 (2006).
55. Kontaridis, M. I., Swanson, K. D., David, F. S., Barford, D., & Neel, B. G. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J. Biol. Chem. 281, 6785-6792 (2006).
56. Tartaglia, M., Martinelli, S., Stella, L., Bocchinfuso, G., Flex, E., Cordeddu, V., et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am. J. Hum. Genet. 78, 279-290 (2006).
57. Martinez-Quintana, E., & Rodriguez-Gonzalez, F. LEOPARD syndrome: clinical features and gene mutations. Mol. Syndromol. 3, 145-157 (2012).
58. Lauriol, J., & Kontaridis, M. I. PTPN11-Associated mutations in the heart: has LEOPARD changed Its RASpots?. Trends Cardiovasc. Med. 21, 97-104 (2011).
59. Komatsuzaki, S., Aoki, Y., Niihori, T., Okamoto, N., Hennekam, R. C., Hopman, S., et al. Mutation analysis of the SHOC2 gene in Noonan-like syndrome and in hematologic malignancies. J. Hum. Genet. 55, 801-809 (2010).
60. Baldassarre, G., Mussa, A., Banaudi, E., Rossi, C., Tartaglia, M., Silengo, M., et al. Phenotypic variability associated with the invariant SHOC2 c.4A4G (p.Ser2Gly) missense mutation. Am. J. Med. Genet. A 164A, 3120-3125 (2014).
61. Lin, A. E., Alexander, M. E., Colan, S. D., Kerr, B., Rauen, K. A., Noonan, J., et al. Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: a Ras/MAPK pathway syndrome. Am. J. Med. Genet. A 155A, 486-507 (2011).
62. Allanson, J. E., Anneren, G., Aoki, Y., Armour, C. M., Bondeson, M. L., Cave, H., et al. Cardio-facio-cutaneous syndrome: does genotype predict phenotype?. Am. J. Med. Genet. C Semin. Med. Genet. 157, 129-135 (2011).
63. Pierpont, M. E., Magoulas, P. L., Adi, S., Kavamura, M. I., Neri, G., Noonan, J., et al. Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 134, e1149-e1162 (2014).
64. Narumi, Y., Aoki, Y., Niihori, T., Neri, G., Cave, H., Verloes, A., et al. Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome. Am. J. Med. Genet. A 143A, 799-807 (2007).
65. Lin, A. E., Birch, P. H., Korf, B. R., Tenconi, R., Niimura, M., Poyhonen, M., et al. Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1. Am. J. Med. Genet. 95, 108-117 (2000).
66. Oderich, G. S., Sullivan, T. M., Bower, T. C., Gloviczki, P., Miller, D. V., Babovic-Vuksanovic, D., et al. Vascular abnormalities in patients with neurofibromatosis syndrome type I: clinical spectrum, management, and results. J. Vasc. Surg. 46, 475-484 (2007).
67. Lama, G., Graziano, L., Calabrese, E., Grassia, C., Rambaldi, P. F., Cioce, F., et al. Blood pressure and cardiovascular involvement in children with neurofibromatosis type1. Pediatr. Nephrol. 19, 413-418 (2004).
68. Brems, H., Pasmant, E., Van Minkelen, R., Wimmer, K., Upadhyaya, M., Legius, E., et al. Review and update of SPRED1 mutations causing Legius syndrome. Hum. Mutat. 33, 1538-1546 (2012).
69. Rauen, K. A., Banerjee, A., Bishop, W. R., Lauchle, J. O., McCormick, F., McMahon, M., et al. Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am. J. Med. Genet. C Semin. Med. Genet. 157, 136-146 (2011).
70. Krab, L. C., De Goede-Bolder, A., Aarsen, F. K., Pluijm, S. M., Bouman, M. J., Van Der Geest, J. N., et al. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA 300, 287-294 (2008).
71. Chen, P. C., Wakimoto, H., Conner, D., Araki, T., Yuan, T., Roberts, A., et al. Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome-Associated Sos1 mutation. J. Clin. Invest. 120, 4353-4365 (2010).
72. Wu, X., Simpson, J., Hong, J. H., Kim, K. H., Thavarajah, N. K., Backx, P. H., et al. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J. Clin. Invest. 121, 1009-1025 (2011).
73. Inoue, S. I., Moriya, M., Watanabe, Y., Miyagawa-Tomita, S., Niihori, T., Oba, D., et al. New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome. Hum. Mol. Genet. 23, 6553-6566 (2014).
74. Marin, T. M., Keith, K., Davies, B., Conner, D. A., Guha, P., Kalaitzidis, D., et al. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-Associated PTPN11 mutation. J. Clin. Invest. 121, 1026-1043 (2011).
75. Hahn, A., Lauriol, J., Thul, J., Behnke-Hall, K., Logeswaran, T., Schanzer, A., et al. Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: palliative treatment with a rapamycin analog. Am. J. Med. Genet. A 167, 744-751 (2015).
76. Bayrak-Toydemir, P., & Stevenson, D. RASA1-related disorders. GeneReviews® [Internet] (University of Washington, Seattle, WA, 2014).
77. Revencu, N., Boon, L. M., Mendola, A., Cordisco, M. R., Dubois, J., Clapuyt, P., et al. RASA1 mutations and associated phenotypes in 68 families with capillary malformation-Arteriovenous malformation. Hum. Mutat. 34, 1632-1641 (2013).